Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015  US-Australian drug discovery company, Novogen, ... of Understanding with the Feinstein Institute for Medical ... to collaborate with the objective of ... The collaboration brings together the drug discovery expertise ... of the Feinstein Institute in neurosciences and oncology. ...
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 /PRNewswire/ ... Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) ... develop clinical applications of induced pluripotent stem cells ... neurological disorders and cancer immunotherapy. The "Takeda-CiRA Joint ... to expedite multiple research projects for drug discovery ...
(Date:4/16/2015)... 16, 2015  Schulman Associates IRB, Inc., the industry-leading ... a long-term lease on Laboratory Drive in the heart ... . The location will house review board and service ... quality reviews and customer service to clients. ... Schulman in the deal, while Capital Associates Management, LLC ...
(Date:4/16/2015)... April 16, 2015  In recognition of World Hemophilia Day, ... advocacy groups to illuminate more than 15 prominent landmarks red ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... evening of April 17, and coincide with hemophilia community events ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4
... , , , ... Amex: CXM ) today announced plans to develop ... by Cardium,s Tissue Repair Company that will initially focus on ... patients with degenerative disc disease. Orthobiologics is a rapidly ...
... YORK, July 30 Stemline Therapeutics, Inc., a clinical stage ... to cancer stem cell targets, today announced that the Company,s ... the New Frontiers in Cancer Drug Development conference which is ... MA. Dr. Bergstein,s presentation, entitled "Developing Drug Candidates Directed ...
... 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... and,producer of prescriptions drugs and licensed national seller ... today reported it received notice,of patent pending from ... of China for its innovative patent application of,Gliclazide-Controlled ...
Cached Biology Technology:Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 2Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 4Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 5Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 6Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 7Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 8Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 9Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 10Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 2Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets 3
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... study of the High Arctic climate roughly 50 million years ... to explain how ancient alligators and giant tortoises were able ... even as they endured six months of darkness each year. ... early Eocene period 52 to 53 million years ago, also ...
... altitude, says a team of researchers from the California ... model, which posited that insects adjust their height by ... This mechanism for controlling altitudein which the insects ... environmentis very similar to the strategy insects use to ...
... of the Galton-Darwin-Wedgwood pedigree was prepared by Harry Hamilton ... Carnegie Institute, and exhibited at the Third International Congress ... Natural History. A photograph of this poster has ... in Kirksville, Missouri alongside a photograph of a poster ...
Cached Biology News:New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 2New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 3New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago 4Fruit flies use horizontal landmarks for altitude control, says Caltech research team 2Fruit flies use horizontal landmarks for altitude control, says Caltech research team 3Fruit flies use horizontal landmarks for altitude control, says Caltech research team 4
Request Info...
... Services include: ,ICC and IHC Protocol ... Analyses ,Antibody Screenings in Animal or ... Labeling of Cells and Tissues ,Peroxidase, ... ,Light, Fluorescent, or Electron Microscopy ,Protein ...
Request Info...
Request Info...
Biology Products: